Search

Displaying results 2851 - 2860 of 10000 in total
  1. Drug

    Safinamide

    go.drugbank.com/drugs/DB06654
    ApprovedInvestigational

    Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  2. Drug

    Adefovir dipivoxil

    go.drugbank.com/drugs/DB00718
    Approved

    Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment … It is ineffective against HIV-1. Adefovir dipivoxil is the diester prodrug of adefovir.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Methylchloroisothiazolinone

    go.drugbank.com/drugs/DB14197
    Approved

    It is also a known dermatological sensitizer and allergen; some of its side effects include flaky or scaly skin, breakouts, redness or itchiness, and moderate to severe swelling in the eye area. … The American Contact Dermatitis Society named Methylchloroisothiazolinone the Contact Allergen of the Year for 2013.

    Synonyms: 5-Chloro-N-methylisothiazolin-3-oneCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    Gemifloxacin

    go.drugbank.com/drugs/DB01155
    ApprovedInvestigational

    It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth. … Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Delamanid

    go.drugbank.com/drugs/DB11637
    ApprovedInvestigational

    Spontaneous resistance to delamanid was observed during treatment, where mutation in one of the 5 F420 coenzymes responsible for bioactivation of delamanid contributes to this effect [L1407]. … In a clinical study involving patients with pulmonary multidrug-resistant tuberculosis or extensively drug-resistant tuberculosis, treatment of delamanid in combination with WHO-recommended optimised background

    Synonyms: (R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazoleCategories: Antiinfectives for Systemic Use, Drugs for Treatment of Tuberculosis
  6. Drug

    Zolpidem

    go.drugbank.com/drugs/DB00425
    ApprovedInvestigational

    It is aimed for use in patients with difficulties initiating sleep. … Research also shows that zolpidem is rapid and effective in restoring brain function for patients in a vegetative state following brain injury.

    Synonyms: N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide
  7. Drug

    Revumenib

    go.drugbank.com/drugs/DB18515
    ApprovedInvestigational

    It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval. … Abnormal gene rearrangements at chromosome locus 11q23, called KMT2A rearrangements or translocations, are present in 5%-10% of patients with acute leukemias and are the sole genetic aberration found in

    Synonyms: Benzamide, n-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-n-(1-methylethyl)-
  8. Drug

    Frangula purshiana bark

    go.drugbank.com/drugs/DB15478
    Approved

    Mixtures: Herborex Fort Lax Liq, Herbalax Forte No 70 Tab
  9. Drug

    Tafasitamab

    go.drugbank.com/drugs/DB15044
    ApprovedInvestigational

    for the treatment of relapsed or refractory DLBCL in adult patients who cannot receive autologous stem cell transplants. … Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies.

  10. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    [L2336] Opicapone is used for adjunct therapy to levodopa and carbidopa in adult patients with Parkinson's disease and end-of-dose motor fluctuations. … Opicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules.